EP Patent

EP2529756B1 — Risperidone and/or Paliperidone implant formulation

Assigned to Laboratorios Farmaceuticos Rovi SA · Expires 2021-05-19 · 5y expired

What this patent protects

Patent listed against Risperdal.

Drugs covered by this patent

Patent Metadata

Patent number
EP2529756B1
Jurisdiction
EP
Classification
—
Expires
2021-05-19
Drug substance claim
No
Drug product claim
No
Assignee
Laboratorios Farmaceuticos Rovi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.